Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
XDx: Funds raised in a recent $26.5 mil. Series D financing, led by Duff, Ackerman & Goodrich, will be used to expand sales and marketing for XDx' AlloMap molecular expression testing technology. The non-invasive test measures gene expression in a patient's blood to prevent physicians from transplanting organs that are genetically incompatible to their recipient. XDx launched the test for use in assessing a heart transplant patient's risk of rejection in January 2005 (1"The Gray Sheet" Jan. 3, 2005, p. 17). A portion of the funds also will support the development of a lung-transplant rejection test, expected to launch in the first half of 2007, as well as an autoimmune indication for its molecular diagnostic. The San Francisco, Calif.-based firm is looking to partner with a pharmaceutical or biotech company, according to CFO Vikram Jog. XDx' technology would be used to identify biomarkers for drug development...